Thymoma Clinical Trials

Thymoma clinical trials serve two purposes: to help researchers determine how effective new therapies are (and whether the emerging options are better than current treatments), and to allow patients to access new therapies before they are available in other settings. Through clinical trials, physicians can discover the most effective doses and delivery methods for new thymoma therapies, and make note of any side effects and the best ways to manage them. At the same time, patients can pursue breakthrough treatments while being carefully monitored by an experienced team of physicians. At Moffitt Cancer Center, our thymoma clinical trials are conducted by the same oncologists who provide our other thymoma treatments. This means that:

  • Participants are monitored by skilled physicians who already understand the unique challenges of thymoma treatment and know how to best utilize options such as chemotherapy, radiation therapy and surgery.
  • Patients who do not benefit from a trial can easily switch to a different dosage or treatment under the care of a team that already understands his or her unique situation.
  • Patients have access to our complete range of treatments – from innovative clinical trial therapies to support services and more – all in one convenient location. This has earned Moffitt the title of Comprehensive Cancer Center, a widely respected designation awarded by the National Cancer Institute.

Moffitt’s thymoma clinical trials continue to lead to more efficient treatment programs, more promising patient outcomes and a higher quality of life for our patients – plus, each trial brings us one step closer to a cure. Advanced molecular therapy options, more targeted radiation therapy methods and therapies for recurrent thymoma are just a few of the areas we are currently investigating through our clinical trial program. There’s no need to obtain a referral to learn more about our thymoma clinical trials. For more information, call 1-888-663-3488 or request an appointment online.